The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...

Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with CURE that the Food and Drug Administration (FDA) removal of primary central ...

Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that ...

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...

Patterns created using advanced fault models provide higher test coverage, improved defect detection, and higher-yielding ...

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, ...

Users running a quantized 7B model on a laptop expect 40+ tokens per second. A 30B MoE model on a high-end mobile device ...

Gold price surged above $5,000 on Monday, February 9, 2026, trading at $5,033 after gaining 1.30% as Wells Fargo Investment Institute dramatically upgraded its year-end forecast to $6,100-$6,300.

Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers-Delivering Risk Prediction Where Proteomics Falls ShortMORRISVILLE, N.C., Feb. 17, 2026 /PRNewswire/ -- Metabolon ...